In March 2025, U.S. markets took a hit as trade tensions flared up again and haven't stopped ever since. The S&P 500 and Nasdaq both dropped over 10% from recent highs, officially entering correction territory. The sell-offI am working as a Business Analyst and Data Engineer in Germany and have started to build up a portfolio focused on Dividend Growth, both on the high and low-end yield spectrum. Primary focus is on Blue Chips with long-reaching dividend track records. I have been investing for 2 years and ...

NEW YORK, April 17, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cerevel Therapeutics Holdings, Inc. (NYSE: ABBV).Shareholders who purchased shares of ABBV during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/cerevel-therapeutics-holdings-inc-loss-submission-form/?id=143352&from ...

Group 1: Company Highlights - AbbVie Inc. has outperformed the Zacks Large Cap Pharmaceuticals industry over the past year with a growth of +10.2% compared to the industry's decline of -12.5%. The company's products, Skyrizi and Rinvoq, are performing well due to new approvals, and robust revenue growth is expected in 2025 following the loss of exclusivity for Humira [4][5] - The TJX Companies, Inc. has outperformed the Zacks Retail – Discount Stores industry over the last six months with a growth of +11.2% compared to +2.2% for the industry. The company benefits from a strong focus on customer experience and consistent increases in customer transactions [5][6] - The Charles Schwab Corp. has underperformed the Zacks Financial – Investment Bank industry over the past six months, with a growth of +5.3% compared to +19.8% for the industry. The company is facing increased expenses due to investments in growth areas and subdued trading revenues [6][7] - Enzo Biochem, Inc. has significantly underperformed the Zacks Medical – Biomedical and Genetics industry over the past year, with a decline of -69.6% compared to -12.6% for the industry. The company faces challenges from market demand and pricing pressures, along with sustained net losses [7][8] - CVD Equipment Corp. has outperformed the Zacks Manufacturing – General Industrial industry over the last six months with a decline of -8.9% compared to -15.2% for the industry. Innovations in products position the company for growth in high-demand markets, despite facing challenges from market overcapacity and fluctuating revenues [8][9] Group 2: Market Trends and Challenges - AbbVie faces near-term headwinds including biosimilar erosion of Humira, competitive pressure on Imbruvica, and slow market growth for Juvederm fillers in the U.S. and China [5] - TJX is experiencing concerns over increased store wage and payroll costs, as well as negative impacts from unfavorable currency translations [6] - Charles Schwab's subdued trading revenues raise concerns due to volatile capital market performance, although opportunistic acquisitions have led to a rise in client assets [7] - Enzo Biochem's long-term recovery is challenged by compliance costs and increased competition, which threaten operational resilience amid macroeconomic issues [8] - CVD Equipment faces challenges from silicon carbide market overcapacity and declining liquidity, which pressure margins in the volatile semiconductor sector [9]

In my 2025 Outlook, I picked AbbVie Pharmaceuticals (NYSE: ABBV) as one to watch this year.Here is what I wrote: AbbVie (ABBV) AbbVie primarily works in immunology, oncology, neuroscience, eye care, and virology. It is also the parent company of Allergan, the maker of Botox. Botox is one of the most well-known and widely used aesthetic treatments globally, primarily known for its cosmetic use in reducing wrinkles and fine lines. Hence, it fits in the “Vanity” trade. The monthly chart shows the correctio ...

For Immediate ReleasesChicago, IL – April 15, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Merck (MRK) and AbbVie (ABBV) .Here are highlights from Tuesday’s Analyst Blog:Merck and AbbVie are leading pharmaceutical companies with strong portfolios in oncology and immunology. While AbbVie also markets products fo ...

Company Overview - Merck (MRK) and AbbVie (ABBV) are leading pharmaceutical companies with strong portfolios in oncology and immunology, with Merck also involved in vaccines, diabetes, virology, and animal health, while AbbVie has a presence in aesthetics, neuroscience, and eye care [1][2] - Oncology accounts for around 50% of Merck's total revenues, with Keytruda, a PD-L1 inhibitor, alone accounting for approximately 50% of its pharmaceutical sales [1][2] AbbVie Analysis - AbbVie's largest segment is immunology, contributing around 50% of its total revenues, with key drugs including Humira, Skyrizi, and Rinvoq [2][3] - The company has successfully managed the loss of exclusivity for Humira by launching new immunology medicines, Skyrizi and Rinvoq, which are performing well and expected to support growth [3][4] - AbbVie has a robust pipeline with several early/mid-stage candidates and anticipates multiple regulatory submissions and approvals in the next 12 months [4] - The company has been active in acquisitions to strengthen its pipeline, particularly in immunology, while also exploring early-stage deals in oncology and neuroscience [4] AbbVie Challenges - AbbVie faces near-term challenges, including biosimilar erosion of Humira, competitive pressure on Imbruvica, and slow market growth for Juvederm fillers in the U.S. and China [5] AbbVie Financials - As of December 31, 2024, AbbVie had $60.3 billion in long-term debt and $6.8 billion in short-term obligations, with cash and cash equivalents of approximately $5.6 billion, resulting in a debt-to-capital ratio of 0.95, significantly higher than the industry average of 0.41 [6] Merck Analysis - Merck has over six blockbuster drugs, with Keytruda being the primary revenue driver, particularly in early-stage non-small cell lung cancer [7] - The company has made significant regulatory and clinical progress in 2024, particularly in oncology and vaccines, and has executed strategic acquisitions [8] Merck Challenges - Merck's sales of Gardasil declined in 2024 due to weak performance in China, and the company is experiencing weakness in its diabetes franchise and generic erosion of some drugs [9] - Concerns are rising about Merck's ability to grow its non-oncology business ahead of Keytruda's loss of exclusivity in 2028 [10] Merck Financials - As of the end of 2024, Merck had cash and cash equivalents of $13.7 billion against long-term debt of $34.5 billion, resulting in a debt-to-capital ratio of 0.42, slightly above the industry average [10] Sales and Earnings Estimates - The Zacks Consensus Estimate for AbbVie's 2025 sales and EPS implies year-over-year increases of 5.7% and 21.4%, respectively [11] - The Zacks Consensus Estimate for Merck's 2025 sales and EPS implies year-over-year increases of 1.3% and 17.1%, respectively [14] Stock Performance - Year-to-date, AbbVie's stock has declined by 0.6%, while Merck's stock has dropped by 19.7%, compared to the industry's decrease of 6.0% [17] Valuation Comparison - Both companies are priced lower than the industry average, with AbbVie trading at a price/earnings ratio of 13.71, higher than Merck's 8.60 [19] - AbbVie's dividend yield is 3.75%, lower than Merck's 4.09% [20] Return on Equity - AbbVie's return on equity stands at 296.3%, significantly higher than Merck's 44.4% [23] Investment Outlook - AbbVie is positioned for continued strong growth, having navigated the challenges of Humira's patent cliff effectively, while Merck faces uncertainties related to Keytruda's upcoming loss of exclusivity [25][26] - AbbVie expects robust mid-single-digit revenue growth in 2025, while Merck's future growth is uncertain due to its reliance on Keytruda [26]

Core Insights - The European Commission has granted marketing authorization for the expanded use of AbbVie's Rinvoq and AstraZeneca's cancer drugs, Imfinzi and Enhertu, indicating positive regulatory developments for these companies [2][4][6][8] - Novartis plans to invest $23 billion over the next five years to enhance its manufacturing and R&D capabilities in the United States, reflecting a strategic shift towards domestic production amid tariff threats [10][11][12] Company Developments - AbbVie's Rinvoq has received approval for treating giant cell arteritis, marking its eighth indication, with ongoing studies for additional autoimmune diseases [4][5] - AstraZeneca's Imfinzi has been approved for use in combination with chemotherapy for non-small cell lung cancer, and Enhertu has received approval for treating specific types of metastatic breast cancer [6][8][9] - Novartis aims to produce 100% of its key medicines in the U.S. through its $23 billion investment, which will create approximately 5,000 new jobs [10][11] Market Context - The pharmaceutical sector has faced challenges, with the NYSE ARCA Pharmaceutical Index declining by 9.8% over the past five trading sessions, and all major stocks in the sector showing negative performance [12][13] - AbbVie experienced the most significant decline among major stocks, dropping by 13.6% in the last five trading sessions [12]

ALERT COMES AT LOW POINT FOR ABBV AND SIGNALS MAJOR REVERSAL OF OVER 15 POINTSToday, AbbVie, Inc. (ABBV) experienced a Power Inflow, a significant event for those who follow where smart money goes and value order flow analytics in their trading decisions. Today, at 11:00 AM on April 9th, a significant trading signal occurred for AbbVie, Inc. (ABBV) as it demonstrated a Power Inflow at a price of $164.86. This indicator is crucial for traders who want to know directionally where institutions and so-called "s ...

Market Overview - Stock markets experienced a significant surge following U.S. President Donald Trump's unexpected reversal on tariffs, with a universal 10% rate applied to all trade partners except China [1][2] Automotive Industry - Major automotive companies saw substantial gains, with Volkswagen, BMW, and Mercedes-Benz Group all increasing by over 9%, and Stellantis rising by 14% [3] - In Asia, Nissan rose by 9.5%, Honda by 8.4%, and Toyota by 7.7%, reflecting a positive market reaction to Trump's 90-day pause announcement [4] Banking Sector - The banking sector recorded sharp gains of 8.61% at market open, recovering from previous declines, with European banks like Banco Santander, Deutsche Bank, and Intesa Sanpaolo rising by 9-11% [5] - UBS also saw a rise of 9.5%, indicating a rebound in investor confidence [5][6] Pharmaceutical Sector - Pharmaceutical stocks rebounded, with Novo Nordisk gaining 10% and other major firms like Novartis and Bayer increasing by over 5% [9] - The sector had previously faced uncertainty due to potential tariffs, but the recent market movement suggests a temporary reprieve [10] Luxury Goods Sector - Luxury stocks, including LVMH and Kering, experienced gains, benefiting from their strong pricing power and ability to pass on costs to consumers [11] - However, analysts caution that a broader economic downturn could impact consumer spending even among wealthier shoppers [12][13] Mining Industry - Mining stocks in Europe performed well, with Anglo American shares jumping 11% and other companies like Antofagasta and Glencore trading up by more than 8% [14] - Despite previous warnings about the impact of trade policies on demand for metals, the sector showed resilience in the current market environment [14]

Core Insights - The article provides an overview of the investment landscape, emphasizing the importance of independent research and verification of information before making investment decisions [2][3]. Group 1 - The article highlights that past performance does not guarantee future results, indicating a need for caution among investors [3]. - It stresses that the opinions presented are based on probabilistic analysis rather than absolute certainty, which reflects the inherent volatility and risk in stock investments [2][3]. - The content is intended for informational purposes and should not be interpreted as personalized investment advice, underscoring the necessity for investors to assess their financial circumstances independently [2][3].